Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 12/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14768863 | 0.91 | PDK2 (0.45) | PDK2APEX1MMP2MMP9MMP8 | |
| SCHEMBL18682727 | 0.90 | APEX1 (0.43) | THRATHRBPDK2APEX1 | |
| SCHEMBL28776646 | 0.88 | PDK2 (0.51) | PDK2APEX1MMP2MMP9MMP8 | |
| SCHEMBL28871391 | 0.88 | PDK2 (0.51) | PDK2APEX1MMP2MMP9MMP8 | |
| SCHEMBL13497474 | 0.87 | PDK2 (0.42) | PDK2APEX1MMP2MMP9MMP8 | |
| SCHEMBL25070269 | 0.85 | APEX1 (0.47) | PDK2APEX1 | |
| SCHEMBL4821046 | 0.85 | APEX1 (0.47) | PDK2APEX1 | |
| SCHEMBL3559881 | 0.84 | PDK2 (0.41) | PDK2APEX1MMP2MMP9MMP8 | |
| SCHEMBL3560148 | 0.84 | PDK2 (0.39) | PDK2APEX1MMP2MMP9MMP8 | |
| SCHEMBL4822886 | 0.84 | PDK2 (0.43) | PDK2APEX1MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7663301-B2 | for use as robust red organic phosphors | GENERAL ELECTRIC COMPANY (US) | 2010-02-16 | — | — | US | disclosed |
| WO-2006076247-A2 | PHOSPHORESCENT FLUORENE, ANTHRACENE AND/OR THIOPHENE SUBSTITUTED METALLO- PORPHYRINS AND RELATED COMPOUNDS | GENERAL ELECTRIC COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060152149-A1 | Porphyrin compositions | GENERAL ELECTRIC COMPANY (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060152149-A1 | Porphyrin compositions | ACP1, MMS19, MVD | THRA 1742/4885THRB 2019/4885PDK2 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.